Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02703051 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT02703051: Completed Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT02703051 is a Phase 1 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02703051, a Phase 1 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
Phase 1, open-label, parallel, active-controlled, multiple IV dose, proof of concept study conducted at one study center in the United States (US).
Interventions
- DRUG Filgrastim
- DRUG Placebo Injection
- DRUG Placebo Infusion
- DRUG GMI-1271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02703051
The ClinicalTrials.gov registry entry for NCT02703051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Filgrastim is the first listed.
NCT02703051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02703051 about?
NCT02703051 is a clinical study titled "A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects". Phase 1, open-label, parallel, active-controlled, multiple IV dose, proof of concept study conducted at one study center in the United States (US).
What is the current status of trial NCT02703051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2015-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02703051?
The interventions under investigation include: Filgrastim (DRUG), Placebo Injection (DRUG), Placebo Infusion (DRUG), GMI-1271 (DRUG).
Who is sponsoring clinical trial NCT02703051?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.